Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
12/2003
12/04/2003WO2003099805A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003WO2003099759A1 Preparation and application of transhintotalphenolic acid
12/04/2003WO2003099324A1 Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
12/04/2003WO2003099317A1 Novel uses of cephaibols
12/04/2003WO2003099309A1 Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits
12/04/2003WO2003099308A1 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng
12/04/2003WO2003099279A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003098992A2 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
12/04/2003WO2003064596A3 Desaturase genes, enzymes encoded thereby, and uses thereof
12/04/2003WO2003063846A3 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
12/04/2003WO2003061593A3 Novel targeted compositions for diagnostic and therapeutic use
12/04/2003WO2003057380A3 Compositions including ammonia oxidizing bacteria and methods of using same
12/04/2003WO2003039523A3 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
12/04/2003WO2003030878A3 Galenic microparticulate oral formulation
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003014145A3 Peptides that bind to atherosclerotic lesions
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002094186A3 Urazole compounds useful as anti-inflammatory agents
12/04/2003WO2002074970A8 A process for the production of an inhibitor of human platelet aggregation and soybean lipoxygenase
12/04/2003US20030225287 Synthesis of chiral 2-alkyl amino acids
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225144 Anticoagulants, methyl (2R,3R)-2-(3-(amino(imino)methyl)benzyl)-3-((4-(1-oxido-4-pyridinyl) benzoyl)amino)butanoate; therapeutic treatment of cardiovascular disorders
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225128 For treating conditions such as erectile dysfunction, cardiovascular disorders, male or female sexual dysfunction, diabetes mellitus, and gastrointestinal disorders
12/04/2003US20030225115 Anticoagulants
12/04/2003US20030225110 Tetrahydroquinoline derivatives as antithrombotic agents
12/04/2003US20030225109 Inducing contraception, treat progesterone-related carcinomas and adenocarcinomas; hormone replacement therapy
12/04/2003US20030225103 Method of using diketopiperazines and composition containing them
12/04/2003US20030225094 E.g, 4-(2-((6R,12aR)-6-benzo(1,3)dioxol-5-yl-1,4-dioxo -3,4,6,7,12,12a-hexahydro-1H-pyrazino-(1',2':1,6)pyrido(3,4-b) indol-2-yl)ethyl)-benzenesulfonamide; inhibitors of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase
12/04/2003US20030225093 Cyclic gmp-specific phosphodiesterase inhibitors
12/04/2003US20030225090 Oxindole derivatives
12/04/2003US20030225086 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225069 Treating solid tumors, including sarcomas and carcinomas, such as astrocytomas, prostate cancer, breast cancer, small cell lung cancer, and ovarian cancer, leukemias, lymphomas, adult T-cell leukemia/lymphoma, etc.
12/04/2003US20030225066 Peritoneal dialysis solution with taurolidine
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030225038 Adenosine receptor antagonists and methods of making and using the same
12/04/2003US20030225033 Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
12/04/2003US20030225007 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224508 Novel vectors and genes exhibiting increased expression
12/04/2003US20030224487 Novel cytokine zcytor17 ligand
12/04/2003US20030224073 Cinnamomi and poria composition, method to prepare same and uses thereof
12/04/2003US20030223956 Macromers having a backbone comprising a polymeric backbone comprising units with a 1,2- diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and other modifiers. When crosslinked, the macromers
12/04/2003CA2487246A1 Novel uses of cephaibols
12/04/2003CA2487167A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/03/2003EP1367066A2 Succinylated fish gelatin
12/03/2003EP1367060A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
12/03/2003EP1367054A1 Heterocyclic factor Xa inhibitors
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366161A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof
12/03/2003EP1366144A2 A device for preparing cells
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366078A2 Ige receptor antagonists
12/03/2003EP1366074A2 Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
12/03/2003EP1366050A2 Condensed pyrazindione derivatives as pde inhibitors
12/03/2003EP1366049A2 Pirazino[1'2':1,6]pyrido[3,4-b]indole derivatives
12/03/2003EP1366045A2 Efficient process for the preparation of a factor xa inhibitor
12/03/2003EP1366035A1 Preparation of warfarin sodium from warfarin sodium-2-propanol clathrate by solvent expulsion
12/03/2003EP1366029A1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents
12/03/2003EP1366024A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
12/03/2003EP1366022A1 Rgd-analog non-peptidic molecules having anti-adhesive, anti-migration and anti-proliferative effects
12/03/2003EP1366016A2 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor
12/03/2003EP1365805A2 Novel targeted compositions for diagnostic and therapeutic use
12/03/2003EP1365793A2 Treatment of inflammatory bowel disease using growth factors
12/03/2003EP1365788A2 Thrombomodulin analogs for use in recovery of signal cord injury
12/03/2003EP1365778A2 Treating pulmonary disorders with gaseous agent causing repletion of gsno
12/03/2003EP1365763A1 Farnesyl protein transferase inhibitor combinations with antiestrogen agents
12/03/2003EP1365752A2 Methods for the treatment of a traumatic central nervous system injury with e.g. allopregnanolone
12/03/2003EP1365750A2 Methods for inactivation of pathogens in biological materials
12/03/2003EP1365651A1 Composition and methods for modulation of vascular structure and/or function
12/03/2003EP1365645A2 Transgenic mice containing targeted gene disruptions
12/03/2003EP1257555B1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/03/2003EP1150963B1 Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them
12/03/2003EP0854715B1 Methods of inhibiting plasminogen activator inhibitor 1
12/03/2003EP0767666B1 Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
12/03/2003CN1460109A Improved specificity in treatment of diseases
12/03/2003CN1460101A Novel compounds inhibiting factor Xa activity
12/03/2003CN1460098A Activator for endogenetic pathway of coagulation and their use for exploring anomalies of coagulation
12/03/2003CN1460018A Implantable gel compositions and method of mfg.
12/03/2003CN1459448A Preparation method of red sageroot total phenolic acid and its use
12/03/2003CN1129608C Method and apparatus for preparing acellular red blood cell substitute
12/03/2003CN1129604C Amino acid derivatives and their use as thrombin inhibitors
12/03/2003CN1129576C Phenyl heterocyclic compound used as epoxy enzyme-2 inhibitor
12/02/2003US6656966 Nitrosated and nitrosylated taxanes, compositions and methods of use
12/02/2003US6656954 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity
1 ... 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 ... 671